[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"petct-imaging\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:petct-imaging":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,41,66],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100617948","phase-2-a-pilot-study-to-correlate-4-18f--fluoro-1-naphthol-18f-4fn-petct-imaging-with-chronic-graft-versus-host-disease-manifestations-100617948",false,"NCT07325253","A Pilot Study to Correlate 4-18F- Fluoro-1-naphthol 18F-4FN PET\u002FCT Imaging With Chronic Graft Versus Host Disease Manifestations","Eligibility Criteria\n\n1. Chronic GVHD involving the joints, defined as any limitation of range of motion measured by Photographic Range Of Motion (PROM). Criteria can be found at (Jagasia, et al. 2015).\n2. Able to give written informed consent.\n3. ≥18 years of age\n4. Creatinine clearance ≥ 30 mL\u002Fmin\u002F1.73m2\n5. Non-joint chronic GVHD diagnostic \u002F distinctive features are allowed.\n6. Subjects may be planned to receive a new systemic therapy for chronic GVHD\n7. Prior\u002Fcontinuing systemic therapy for chronic GVHD is allowed\n8. KPS ≥ 20\n9. Ability to understand and the willingness to sign a written informed consent document.\n10. The effects of the study agent on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. (Refer to Pregnancy Assessment Policy MD Anderson Institutional Policy # CLN1114). This includes all female participants, between the onset of menses (as early as 8 years of age) and 55 years unless the participant presents with an applicable exclusionary factor which may be one of the following:\n\n    * Postmenopausal (no menses in greater than or equal to 12 consecutive months).\n    * History of hysterectomy or bilateral salpingo-oophorectomy.\n    * Ovarian failure (Follicle Stimulating Hormone and Estradiol in menopausal range, who have received Whole Pelvic Radiation Therapy).\n    * History of bilateral tubal ligation or another surgical sterilization procedure.\n\n      * Approved methods of birth control are as follows: Hormonal contraception (i.e. birth control pills, injection, implant, transdermal patch, vaginal ring), Intrauterine device (IUD), Tubal Ligation or hysterectomy, Subject\u002FPartner post vasectomy, Implantable or injectable contraceptives, and condoms plus spermicide. Not engaging in sexual activity for the total duration of the trial and the drug washout period is an acceptable practice; however periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.\n11. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of study agent administration.\n\nExclusion Criteria\n\n1. Unable to comply with all study procedures (for example, participants who are unable to come to all follow up visits because they live far away from the transplant center)\n2. Pregnant or lactating women: pregnant women are excluded from this study because the effects of \\[18F\\]4FN in pregnancy are not known.\n3. Subjects with contraindications to the use of \\[18F\\]4FN including confirmed allergy.\n4. Participants with a body weight of 400 pounds or more, or a body habitus which precludes their entry into the bore of the PET\u002FCT scanner, because the hardware is not intended to support that weight.\n5. Any additional medical condition, serious concurrent illness, or other extenuating circumstance that, in the opinion of the investigator, may significantly interfere with study compliance.\n6. Children below the age of 18 are excluded because of the unknown but potential risks of administration of radiopharmaceuticals to minors.","ALL","18 Years",{"count":18,"type":19},16,"ESTIMATED","INTERVENTIONAL",[22],"PHASE2","To study the safety and possible side effects of using the imaging agent 4-\\[18F\\]Fluoro-1-Naphthol (also called \\[18F\\]4FN) in PET\u002FCT scans for participants with chronic GVHD.",[25,26,27],"Pilot Study","PET\u002FCT Imaging","Host Disease Manifestation","RECRUITING","2026-06-09",{"date":31,"type":32},"2026-06-10","ACTUAL",{"date":34,"type":32},"2025-11-18",{"date":36,"type":19},"2030-01-03",{"name":38,"class":39},"M.D. Anderson Cancer Center","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":48,"sex":15,"minAge":16,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":20,"phases":52,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":40},"100586155","study-on-c-met-targeted-petct-imaging-in-nsclc-100586155","NCT06911697","Study on c-Met Targeted PET\u002FCT Imaging in NSCLC","In Vivo Detection of c-Met Activation Status by Specific PET\u002FCT Imaging Based on 18F Labeled Small Molecule TKI","Inclusion Criteria:\n\n1. Age range 18-75 years, open to both male and female participants;\n2. Normal hepatic\u002Frenal function and cardiac function;\n3. Expected survival of at least 12 weeks;\n4. Good adherence to follow-up;\n5. Presence of at least one measurable target lesion according to RECIST 1.1 criteria;\n6. Women of childbearing age (15-49 years) must undergo a pregnancy test within seven days prior to the commencement of the study and test negative; sexually active male and female participants must agree to utilize effective contraception to prevent pregnancy during the study and for three months following the final examination;\n7. Patients for whom a clinical physician recommends PET\u002FCT scans for the diagnosis and staging of tumors;\n8. Participants must fully understand and voluntarily agree to participate in the study, and must sign an informed consent form.\n\nExclusion Criteria:\n\n1. Severe abnormalities in liver and renal function and blood counts;\n2. Patients planning to conceive;\n3. Pregnant or lactating women;\n4. Individuals unable to lie flat for thirty minutes;\n5. Individuals who refuse to participate in this clinical study;\n6. Individuals suffering from claustrophobia or other psychiatric disorders;\n7. Other situations deemed unsuitable for trial participation by the researchers.",true,"75 Years",{"count":51,"type":19},88,[53],"NA","The investigators developed a 18F labeled small molecule, 18F-TSPF, based on c-Met TKI, as a targeted molecular imaging agent for noninvasive and repeatable detecting c-Met activation status.",[26,56],"NSCLC","2025-03-28",{"date":59,"type":32},"2025-04-04",{"date":61,"type":32},"2023-10-26",{"date":63,"type":19},"2025-06-28",{"name":65,"class":39},"Xilin Sun",{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":72,"targetDuration":4,"studyType":20,"phases":74,"briefSummary":76,"conditions":77,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":40},"100481440","early-phase-1-68ga-rm26-rgd-petct-imaging-in-the-grpr-and-v3-positive-tumor-patients-100481440","NCT05549024","68Ga-RM26-RGD PET\u002FCT Imaging in the GRPR and αvβ3 Positive Tumor Patients","Inclusion Criteria:\n\n* patients with confirmed or suspected breast\u002Fbrain\u002Fprostate cancer;\n* 68Ga-RM26-RGD and 18F-FDG(or 68Ga-RM26 or 68Ga-RGD) PET\u002FCT within 2 week;\n* signed written consent.\n\nExclusion Criteria:\n\n* pregnancy;\n* breastfeeding;\n* any medical condition that in the opinion of the investigator may significantly interfere with study compliance.",{"count":73,"type":19},90,[75],"EARLY_PHASE1","Based on the high expression of specific receptors on the surface of diseased tissues and neovascularization, noninvasive targeted molecular imaging can be used to visualize lesions in vitro by combining specific ligands labeled with short half-life isotopes. In this study, a novel dual-target imaging agent 68Ga-RM26-RGD was used for clinical study of tumor PET\u002FCT imaging to further verify its clinical application value.",[78,79,80,26],"Breast Cancer","Prostate Cancer","Brain Tumor","2024-07-03",{"date":83,"type":32},"2024-07-05",{"date":85,"type":32},"2022-08-16",{"date":87,"type":19},"2026-12-31",{"name":89,"class":39},"Peking Union Medical College Hospital"]